PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2026-03-14

Date Title Company
14-Mar-2026 YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD) Businesswire